Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice.

Lehrer AT, Wong TS, Lieberman MM, Humphreys T, Clements DE, Bakken RR, Hart MK, Pratt WD, Dye JM.

Vaccine. 2018 May 24;36(22):3090-3100. doi: 10.1016/j.vaccine.2017.01.068. Epub 2017 Feb 16.

PMID:
28216187
2.

Characterization of a Cynomolgus Macaque Model of Pneumonic Plague for Evaluation of Vaccine Efficacy.

Fellows P, Price J, Martin S, Metcalfe K, Krile R, Barnewall R, Hart MK, Lockman H.

Clin Vaccine Immunol. 2015 Sep;22(9):1070-8. doi: 10.1128/CVI.00290-15. Epub 2015 Jul 29.

3.

13-Deoxytetrodecamycin, a new tetronate ring-containing antibiotic that is active against multidrug-resistant Staphylococcus aureus.

Gverzdys T, Hart MK, Pimentel-Elardo S, Tranmer G, Nodwell JR.

J Antibiot (Tokyo). 2015 Nov;68(11):698-702. doi: 10.1038/ja.2015.60. Epub 2015 May 27.

PMID:
26014719
4.

Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.

Aichinger G, Grohmann-Izay B, van der Velden MV, Fritsch S, Koska M, Portsmouth D, Hart MK, El-Amin W, Kistner O, Barrett PN.

Clin Vaccine Immunol. 2015 Jan;22(1):46-55. doi: 10.1128/CVI.00275-14. Epub 2014 Oct 29.

5.

Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.

Reed DS, Glass PJ, Bakken RR, Barth JF, Lind CM, da Silva L, Hart MK, Rayner J, Alterson K, Custer M, Dudek J, Owens G, Kamrud KI, Parker MD, Smith J.

J Virol. 2014 Oct;88(20):12077-86. doi: 10.1128/JVI.01406-14. Epub 2014 Aug 13.

6.

Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.

Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, Stonier SW, Muhammad MA, Bakken RR, Prugar LI, Olinger GG, Groebner JL, Lee JS, Pratt WD, Custer M, Kamrud KI, Smith JF, Hart MK, Dye JM.

J Virol. 2013 May;87(9):4952-64. doi: 10.1128/JVI.03361-12. Epub 2013 Feb 13.

7.

Designing and testing broadly-protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage.

Fenimore PW, Muhammad MA, Fischer WM, Foley BT, Bakken RR, Thurmond JR, Yusim K, Yoon H, Parker M, Hart MK, Dye JM, Korber B, Kuiken C.

PLoS One. 2012;7(10):e44769. doi: 10.1371/journal.pone.0044769. Epub 2012 Oct 3.

8.

Histiocytic sarcoma in the bronchoalveolar lavage fluid.

Dvorak LA, Hart MK, Cioc AM, Schmechel SC, Jessurun J, Pambuccian SE.

Diagn Cytopathol. 2013 Nov;41(11):965-70. doi: 10.1002/dc.22876. Epub 2012 Sep 25. No abstract available.

PMID:
23008273
9.

Osteoid in cellblock sections of ascitic fluid: a clue for the diagnosis of hepatoblastoma.

Hart MK, Conway AB, Reed RC, Carlos Manivel J, Pambuccian SE.

Diagn Cytopathol. 2013 Jun;41(6):533-5. doi: 10.1002/dc.22828. Epub 2012 Feb 23. No abstract available.

PMID:
22362646
10.

A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals.

Ehrlich HJ, Singer J, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Portsmouth D, Kistner O, Barrett PN.

Clin Infect Dis. 2012 Apr;54(7):946-54. doi: 10.1093/cid/cir959. Epub 2012 Jan 19.

11.

Clinical development of a Vero cell culture-derived seasonal influenza vaccine.

Ehrlich HJ, Berezuk G, Fritsch S, Aichinger G, Singer J, Portsmouth D, Hart MK, El-Amin W, Kistner O, Barrett PN.

Vaccine. 2012 Jun 19;30(29):4377-86. doi: 10.1016/j.vaccine.2011.11.114. Epub 2011 Dec 13.

PMID:
22172502
12.

Butterfly-shaped nuclei in cerebrospinal fluid relapse of acute promyelocytic leukemia.

Hart MK, Conway AB, Cioc AM, McKenna RW, Pambuccian SE.

Diagn Cytopathol. 2012 Nov;40(11):987-90. doi: 10.1002/dc.21789. Epub 2011 Nov 18. No abstract available.

PMID:
22102334
13.

Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges.

Hart MK, Saviolakis GA, Welkos SL, House RV.

Adv Prev Med. 2012;2012:731604. doi: 10.1155/2012/731604. Epub 2011 Oct 17.

14.

"Cannonballs" and psammoma bodies: unusual cytologic features of metastatic pulmonary small-cell carcinoma in a pleural effusion.

Conway AB, Hart MK, Jessurun J, Pambuccian SE.

Diagn Cytopathol. 2013 Mar;41(3):247-52. doi: 10.1002/dc.21770. Epub 2011 Oct 11.

PMID:
21987407
15.

Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial.

Barrett PN, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Kistner O, Ehrlich HJ.

Lancet. 2011 Feb 26;377(9767):751-9. doi: 10.1016/S0140-6736(10)62228-3. Epub 2011 Feb 15.

PMID:
21329971
16.

Antibody to the E3 glycoprotein protects mice against lethal venezuelan equine encephalitis virus infection.

Parker MD, Buckley MJ, Melanson VR, Glass PJ, Norwood D, Hart MK.

J Virol. 2010 Dec;84(24):12683-90. doi: 10.1128/JVI.01345-10. Epub 2010 Oct 6.

17.

Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V).

Fellows P, Adamovicz J, Hartings J, Sherwood R, Mega W, Brasel T, Barr E, Holland L, Lin W, Rom A, Blackwelder W, Price J, Morris S, Snow D, Hart MK.

Vaccine. 2010 Nov 16;28(49):7748-56. doi: 10.1016/j.vaccine.2010.09.062. Epub 2010 Oct 15.

PMID:
20920572
19.

Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.

Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL.

Vaccine. 2010 Apr 19;28(18):3143-51. doi: 10.1016/j.vaccine.2010.02.056. Epub 2010 Mar 1.

20.

Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB.

Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL.

Vaccine. 2010 Jan 22;28(4):1031-40. doi: 10.1016/j.vaccine.2009.10.126. Epub 2009 Nov 13.

21.

Telemetric analysis to detect febrile responses in mice following vaccination with a live-attenuated virus vaccine.

Martin SS, Bakken RR, Lind CM, Reed DS, Price JL, Koeller CA, Parker MD, Hart MK, Fine DL.

Vaccine. 2009 Nov 16;27(49):6814-23. doi: 10.1016/j.vaccine.2009.09.013. Epub 2009 Sep 15.

22.

Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain.

Lee JE, Kuehne A, Abelson DM, Fusco ML, Hart MK, Saphire EO.

J Mol Biol. 2008 Jan 4;375(1):202-16. Epub 2007 Oct 16.

23.

Quality of life and physical performance in land- and water-based pulmonary rehabilitation.

Lotshaw AM, Thompson M, Sadowsky HS, Hart MK, Millard MW.

J Cardiopulm Rehabil Prev. 2007 Jul-Aug;27(4):247-51.

PMID:
17667023
24.

Statistical process control for hospitals: methodology, user education, and challenges.

Matthes N, Ogunbo S, Pennington G, Wood N, Hart MK, Hart RF.

Qual Manag Health Care. 2007 Jul-Sep;16(3):205-14.

PMID:
17627215
25.

Control limits for p control charts with small subgroup sizes.

Hart MK, Hart RF, Schmaltz S.

Qual Manag Health Care. 2007 Apr-Jun;16(2):123-9.

PMID:
17426610
26.

Evolutionary stability of egg trading and parceling in simultaneous hermaphrodites: the chalk bass revisited.

Crowley PH, Hart MK.

J Theor Biol. 2007 Jun 7;246(3):420-9. Epub 2007 Jan 30.

PMID:
17335851
27.

Density-dependent habitat selection and performance by a large mobile reef fish.

Lindberg WJ, Frazer TK, Portier KM, Vose F, Loftin J, Murie DJ, Mason DM, Nagy B, Hart MK.

Ecol Appl. 2006 Apr;16(2):731-46.

PMID:
16711059
28.

Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.

Wang D, Raja NU, Trubey CM, Juompan LY, Luo M, Woraratanadharm J, Deitz SB, Yu H, Swain BM, Moore KM, Pratt WD, Hart MK, Dong JY.

J Virol. 2006 Mar;80(6):2738-46.

29.

X and s charts for health care comparisons.

Hart MK, Robertson JW, Hart RF, Schmaltz S.

Qual Manag Health Care. 2006 Jan-Mar;15(1):2-14.

PMID:
16456476
30.

Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins.

Olinger GG, Bailey MA, Dye JM, Bakken R, Kuehne A, Kondig J, Wilson J, Hogan RJ, Hart MK.

J Virol. 2005 Nov;79(22):14189-96.

31.

Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection.

Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL, Hart MK, Bavari S.

J Immunol. 2005 Jul 15;175(2):1184-91.

32.

Application of variables control charts to risk-adjusted time-ordered healthcare data.

Hart MK, Robertson JW, Hart RF, Lee KY.

Qual Manag Health Care. 2004 Apr-Jun;13(2):99-119.

PMID:
15127690
33.

Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus.

Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, Schmaljohn A, Lee J, Hart MK, Vanderzanden L, Custer D, Bray M, Ruff A, Ivins B, Bassett A, Rossi C, Schmaljohn C.

Vaccine. 2003 Sep 8;21(25-26):4071-80.

PMID:
12922144
34.

Vaccine research efforts for filoviruses.

Hart MK.

Int J Parasitol. 2003 May;33(5-6):583-95. Review.

PMID:
12782057
35.

Application of attribute control charts to risk-adjusted data for monitoring and improving health care performance.

Hart MK, Lee KY, Hart RF, Robertson JW.

Qual Manag Health Care. 2003 Jan-Mar;12(1):5-19.

PMID:
12593370
36.

Histamine metabolism in the visual system of the horseshoe crab Limulus polyphemus.

Battelle BA, Hart MK.

Comp Biochem Physiol A Mol Integr Physiol. 2002 Sep;133(1):135-42.

PMID:
12160879
37.

Absence of mycoplasma contamination in the anthrax vaccine.

Hart MK, Del Giudice RA, Korch GW Jr.

Emerg Infect Dis. 2002 Jan;8(1):94-6. No abstract available.

38.

Ebola virus: the search for vaccines and treatments.

Wilson JA, Bosio CM, Hart MK.

Cell Mol Life Sci. 2001 Nov;58(12-13):1826-41. Review.

PMID:
11766882
39.

Onset and duration of protective immunity to IA/IB and IE strains of Venezuelan equine encephalitis virus in vaccinated mice.

Hart MK, Lind C, Bakken R, Robertson M, Tammariello R, Ludwig GV.

Vaccine. 2001 Nov 12;20(3-4):616-22.

PMID:
11672929
40.

Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins.

Wilson JA, Bray M, Bakken R, Hart MK.

Virology. 2001 Aug 1;286(2):384-90.

41.
42.

Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate.

Hart MK, Caswell-Stephan K, Bakken R, Tammariello R, Pratt W, Davis N, Johnston RE, Smith J, Steele K.

Vaccine. 2000 Jul 1;18(26):3067-75.

PMID:
10825611
43.

Epitopes involved in antibody-mediated protection from Ebola virus.

Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL, Hart MK.

Science. 2000 Mar 3;287(5458):1664-6.

45.
46.
47.
48.

Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-I retroviral infections.

Hart MK, Palker TJ, Haynes BF.

Pharm Biotechnol. 1995;6:821-45. Review. No abstract available.

PMID:
7551251
49.

Application of control chart statistics to blood pressure measurement variability in the primary care setting.

Nelson FE, Hart MK, Hart RF.

J Am Acad Nurse Pract. 1994 Jan;6(1):17-28.

PMID:
8003351
50.

Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein.

Haynes BF, Arthur LO, Frost P, Matthews TJ, Langlois AJ, Palker TJ, Hart MK, Scearce RM, Jones DM, McDanal C, et al.

J Exp Med. 1993 Mar 1;177(3):717-27.

Supplemental Content

Support Center